Burden of serious fungal infections in the Netherlands
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Summary: Background: Fungal diseases have an ever‐increasing global disease burden, although regional estimates for specific fungal diseases are often unavailable or dispersed. Objectives: Here, we report the current annual burden of life‐threatening and debilitating fungal diseases in the Netherlands. Methods: The most recent available epidemiological data, reported incidence and prevalence of fungal diseases were used for calculations. Results: Overall, we estimate that the annual burden of serious invasive fungal infections in the Netherlands totals 3 185 patients, including extrapulmonary or disseminated cryptococcosis (n = 9), pneumocystis pneumonia (n = 740), invasive aspergillosis (n = 1 283), chronic pulmonary aspergillosis (n = 257), invasive Candida infections (n = 684), mucormycosis (n = 15) and Fusarium keratitis (n = 8). Adding the prevalence of recurrent vulvo‐vaginal candidiasis (n = 220 043), allergic bronchopulmonary aspergillosis (n = 13 568) and severe asthma with fungal sensitisation (n = 17 695), the total debilitating burden of fungal disease in the Netherlands is 254 491 patients yearly, approximately 1.5% of the country's population. Conclusion: We estimated the annual burden of serious fungal infections in the Netherlands at 1.5% of the population based on previously reported modelling of fungal rates for specific populations at risk. With emerging new risk groups and increasing reports on antifungal resistance, surveillance programmes are warranted to obtain more accurate estimates of fungal disease epidemiology and associated morbidity and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Agarwal, R., Chakrabarti, A., Shah, A., Gupta, D., Meis, J. F., Guleria, R., Moss, R., Denning, D. W., & ABPA complicating asthma ISHAM working group (2013) · Clinical & Experimental Allergy · doi:10.1111/cea.12141 · Cited by 896
Self-citationSchauwvlieghe, A. F. A. D., Rijnders, B. J. A., Philips, N., Verwijs, R., Vanderbeke, L., Van Tienen, C., Lagrou, K., Verweij, P. E., Van de Veerdonk, F. L., Gommers, D., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30274-1 · Cited by 886
Self-citationDenning, D. W., Pleuvry, A., & Cole, D. C. (2013) · Medical Mycology · doi:10.3109/13693786.2012.738312 · Cited by 495
Self-citationUnderlying conditions in chronic pulmonary aspergillosis including simple aspergilloma
Smith, N. L., & Denning, D. W. (2011) · European Respiratory Journal · doi:10.1183/09031936.00054810 · Cited by 449
Self-citationGlobal burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis
Denning, D., Pleuvry, A., & Cole, D. (2011) · Bulletin of the World Health Organization · doi:10.2471/blt.11.089441 · Cited by 420
Kett, D. H., Azoulay, E., Echeverria, P. M., & Vincent, J.-L. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318206c1ca · Cited by 389
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007)
Lortholary, O., Gangneux, J.-P., Sitbon, K., Lebeau, B., de Monbrison, F., Le Strat, Y., Coignard, B., Dromer, F., & Bretagne, S. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03548.x · Cited by 331
Bassetti, M., Giacobbe, D. R., Vena, A., Trucchi, C., Ansaldi, F., Antonelli, M., Adamkova, V., Alicino, C., Almyroudi, M.-P., Atchade, E., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2497-3 · Cited by 270
Foxman, B., Muraglia, R., Dietz, J.-P., Sobel, J. D., & Wagner, J. (2013) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0b013e318273e8cf · Cited by 261
Influenza-associated Aspergillosis in Critically Ill Patients
van de Veerdonk, F. L., Kolwijck, E., Lestrade, P. P. A., Hodiamont, C. J., Rijnders, B. J. A., van Paassen, J., Haas, P.-J., Oliveira dos Santos, C., Kampinga, G. A., Bergmans, D. C. J. J., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201612-2540le · Cited by 230
Self-citationSevere asthma with fungal sensitization
Agarwal, R. (2011) · Current Allergy and Asthma Reports · doi:10.1007/s11882-011-0217-4 · Cited by 188
Estimating the burden of invasive and serious fungal disease in the United Kingdom
Pegorie, M., Denning, D. W., & Welfare, W. (2017) · Journal of Infection · doi:10.1016/j.jinf.2016.10.005 · Cited by 104
Self-citationXu, H., Li, L., Huang, W.-J., Wang, L.-X., Li, W.-F., & Yuan, W.-F. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03503.x · Cited by 95
Yan, X., Li, M., Jiang, M., Zou, L., Luo, F., & Jiang, Y. (2009) · Cancer · doi:10.1002/cncr.24559 · Cited by 94
The burden of fungal disease in Denmark
Mortensen, K. L., Denning, D. W., & Arendrup, M. C. (2015) · Mycoses · doi:10.1111/myc.12383 · Cited by 27
Self-citation
Cited by
COVID-19 Associated Pulmonary Aspergillosis
Koehler, P., Cornely, O. A., Böttiger, B. W., Dusse, F., Eichenauer, D. A., Fuchs, F., Hallek, M., Jung, N., Klein, F., Persigehl, T., et al. (2020) · Mycoses · doi:10.1111/myc.13096 · Cited by 547
Bassetti, M., Giacobbe, D. R., Vena, A., Trucchi, C., Ansaldi, F., Antonelli, M., Adamkova, V., Alicino, C., Almyroudi, M.-P., Atchade, E., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2497-3 · Cited by 270
COVID‐19–associated pulmonary aspergillosis: a prospective single‐center dual case series
Meijer, E. F. J., Dofferhoff, A. S. M., Hoiting, O., & Meis, J. F. (2021) · Mycoses · doi:10.1111/myc.13254 · Cited by 56
Self-citation
Metadata
- Authors
- Buil, J. B., Meijer, E. F. J., Denning, D. W., Verweij, P. E., & Meis, J. F.
- Venue
- Mycoses
- Publisher
- Wiley
- Published
- 2020-04-28
- Volume
- 63
- Issue
- 6
- Pages
- 625-631
- ISSN
- 0027-5557 (ISSN-L)
- 0933-7407
- 1439-0507
- OpenAlex
- W3016614995
- Cited by
- 40
- References
- 16
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.